Evidence map›Paper›PMID 31747033›Full record

ArticleJAMA network open2019

Comparison of HPV-16 and HPV-18 Genotyping and Cytological Testing as Triage Testing Within Human Papillomavirus-Based Screening in Mexico.

Leticia Torres-Ibarra, Jack Cuzick, Attila T Lorincz, Donna Spiegelman, Eduardo Lazcano-Ponce, Eduardo L Franco, Anna Barbara Moscicki, Salaheddin M Mahmud, Cosette M Wheeler, Berenice Rivera-Paredez and 4 more

Open access · goldAbstract readComparative StudyMulticenter Study
In one paragraph

Article in JAMA network open, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.

0numbers the graph read from it
0cells of the map it votes in
34citing papers in PubMed
6.2field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

34 citing papers in PubMed, 71 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Cost-benefit analysis of p16Infectious agents and cancer · 2025
    Article
  6. Spatial Epidemiology of Human Papillomavirus Screening Coverage in Mexico, 2013-2019.Asian Pacific journal of cancer prevention : APJCP · 2025
    Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Histologıcal results of HPV genotyping from a colposcopy center.Archives of gynecology and obstetrics · 2023
    Article
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 9 institutions in 4 countries.

Leticia Torres-IbarraCenter for Population Health Research, National Institute of Public Health, Cuernavaca, Mexico.
Jack CuzickWolfson Institute of Preventive Medicine Centre for Cancer Prevention, Queen Mary University, London, United Kingdom.
Attila T LorinczWolfson Institute of Preventive Medicine Centre for Cancer Prevention, Queen Mary University, London, United Kingdom.
Donna SpiegelmanCenter for Methods in Implementation and Prevention Science, Yale School of Public Health, New Haven, Connecticut.
Eduardo Lazcano-PonceCenter for Population Health Research, National Institute of Public Health, Cuernavaca, Mexico.
Eduardo L FrancoDivision of Cancer Epidemiology, McGill University, Montreal, Quebec, Canada.
Anna Barbara MoscickiDavid Geffen School of Medicine, University of California, Los Angeles.
Salaheddin M MahmudVaccine and Drug Evaluation Centre, Department of Community Health Sciences, University of Manitoba, Winnipeg, Manitoba, Canada.
Cosette M WheelerCenter for HPV Prevention, New Mexico Comprehensive Cancer Center, University of New Mexico, Albuquerque.
Berenice Rivera-ParedezResearch Center on Policies, Population, and Health, Faculty of Medicine, National Autonomous University of Mexico, Mexico City, Mexico.
Rubí Hernández-LópezCenter for Population Health Research, National Institute of Public Health, Cuernavaca, Mexico.
Leith León-MaldonadoCenter for Population Health Research, Consejo Nacional de Ciencia y Tecnología, National Institute of Public Health, Cuernavaca, Mexico.
Jorge SalmerónResearch Center on Policies, Population, and Health, Faculty of Medicine, National Autonomous University of Mexico, Mexico City, Mexico.
FRIDA Study Group.
Instituto Nacional de Salud Pública · MXQueen Mary University of London · GBUniversidad Nacional Autónoma de México · MXConsejo Nacional de Humanidades, Ciencias y Tecnologías · MXMcGill University · CANew Mexico Cancer Center · USUniversity of California, Los Angeles · USUniversity of Manitoba · CAYale University · US

Funding

Yale Clinical and Translational Science Award (U Component)UL1TR001863 · NCATS · YALE UNIVERSITY · PI John H. Krystal, LUCILA OHNO-MACHADO · 2016 to 2026
$102.9M
Comprehensive Translational Science Analytics Tools for the Global Health AgendaDP1ES025459 · NIEHS · YALE UNIVERSITY · PI SPIEGELMAN, DONNA L · 2014 to 2018
$4.1M
NCATS NIH HHS UL1 TR001863NIEHS NIH HHS DP1 ES025459
6 · The paper itself

Abstract

Importance: Triage tests enhance the efficiency cervical cancer screening based on human papillomavirus (HPV), but the best approach for maximizing programmatic effectiveness is still uncertain, particularly in a real-world scenario. Objective: To compare the clinical performance of 6 triage strategies based on liquid-based cytology (LBC) and HPV-16 and HPV-18 genotyping individually or in combination as sequential triage tests to detect cervical intraepithelial neoplasia (CIN) grade 2 or higher among women with high-risk HPV. Design, Setting, and Participants: This diagnostic study of routine cervical cancer screening was conducted at 100 primary health centers in Tlaxcala, Mexico. Women aged 30 to 64 years were recruited from August 1, 2013, to February 24, 2016, as part of the Forwarding Research for Improved Detection and Access for Cervical Cancer Screening and Triage study. Six triage scenarios for referral to colposcopy were examined: (1) LBC testing that found atypical squamous cells of undetermined significance (ASC-US) or worse, (2) positive results in HPV-16 genotyping, (3) positive results in HPV-18 genotyping, (4) positive results in HPV-16/HPV-18 genotyping, (5) positive results in HPV-16 genotyping or, if genotyping results were negative, reflex LBC testing that found ASC-US or worse, and (6) positive results in HPV-16/HPV-18 genotyping or, if genotyping results were negative, reflex LBC testing that found ASC-US or worse. Data were analyzed from October 2017 to August 2018. Exposures: Liquid-based cytological testing with simultaneous HPV-16 and HPV-18 genotyping. Women whose HPV genotyping results were positive for HPV-16 or HPV-18 or whose LBC results found ASC-US or worse and a random set of negative and normal results were referred to colposcopy with histologic analysis used for disease confirmation. Main Outcomes and Measures: Clinical performance of each test strategy for detection of CIN grade 2 or higher. Secondary outcomes included resource utilization of each triage scenario, measured by the number of tests performed, the referral rate for colposcopy, and the numbers of colposcopies per CIN grade 2 or higher detected. Results: A total of 36 212 women (median [interquartile range] age, 40 [35-47] years) were screened, and 4051 women (11.2%) had high-risk HPV. Of these women, 1109 (24.6%) were found to have HPV-16, HPV-18, or ASC-US or worse. Further histologic testing detected CIN grade 2 or higher in 110 of 788 women (14.0%) who underwent follow-up colposcopy. Sensitivity and specificity for 3 main triage strategies were 42.9% and 74.0% for LBC; 58.3% and 54.4% for HPV-16/HPV-18 genotyping; and 86.6% and 34.0% for HPV-16/HPV-18 genotyping with reflex LBC. The referral rate to colposcopy was 29% for HPV-16/HPV-18 with reflex LBC, which was 2-fold higher than the referral rate of 12% for LBC. Conclusions and Relevance: Triage of women with high-risk HPV with HPV-16/HPV-18 genotyping with reflex LBC was significantly associated with improvement in detection of CIN grade 2 or higher compared with LBC alone. The benefit of disease prevented may outweigh the cost of increasing requirements for colposcopy services in settings with limited adherence to follow-up after a positive screening result.

Indexed as

AdultColposcopyEarly Detection of CancerFemaleGenotypeHuman papillomavirus 16Human papillomavirus 18HumansLiquid BiopsyMexicoMiddle AgedPapillomavirus InfectionsUterine Cervical DysplasiaUterine Cervical Neoplasms

Identifiers

PMID31747033
PMCPMC6902808
OpenAlexW2990635021

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.